Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma

Liu, Ling; Dilworth, David; Gao, Luzhang; Monzon, Jose Gerard; Summers, Ann; Lassam, Norman J.; Hogg, David

doi:10.1038/5082

Cited by 249 publications

(188 citation statements)

References 20 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…Germline mutations in critical regions of the p16 INKa promoter could reduce or abolish promoter function, resulting in a genetic predisposition to disease. Yet, to date, only three variants localised in the 5 0 UTR of p16 INKa (À14C4T, À33 G4C, À34 G4A) have been characterised in melanoma patients (Liu et al, 1999) (Hashemi et al, 2000) (Auroy et al, 2001), of which only the latter one has a proved functional effect (Liu et al, 1999). This particular mutation localised 34 bp upstream from the ATG translation initiation codon, creates an aberrant initiation codon, and has been detected in two MPM patients and in two melanoma families.…”

Section: Discussionmentioning

confidence: 99%

Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma

et al. 2004

View full text Add to dashboard Cite

Germline anomalies of the INK4a-ARF and Cdk4 genes were sought in a series of 89 patients suspected of having a genetic predisposition to melanoma. Patients were selected based on the following criteria: (a) familial melanoma (23 cases), (b) multiple primary melanoma (MPM; 18 cases), (c) melanoma and additional unrelated cancers (13 cases), (d) age at diagnosis less than 25 years (21 cases), and (e) nonphoto-induced melanoma (NPIM; 14 cases). Mutations of INK4a-ARF and Cdk4 were characterised by automated sequencing, and germline deletions of INK4a-ARF were also examined by real-time quantitative PCR. Seven germline changes of INK4a-ARF, five of which were novel, were found in seven patients (8%). Four were very likely to be pathogenic mutations and were found in three high-risk melanoma families and in a patient who had a pancreatic carcinoma in addition to melanoma. Three variants of uncertain significance were detected in one MPM patient, one patient o25 years, and one NPIM patient. No germline deletion of INK4a-ARF was found in 71 patients, and no Cdk4 mutation was observed in the 89 patients. This study confirms that INK4a-ARF mutations are infrequent outside stringent familial criteria, and that germline INK4a-ARF deletions are rarely involved in genetic predisposition to melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Prior to the sequence analysis of CDK6, we screened each of the 60 DNA samples for CDKN2A and CDK4 germline mutations. The CDKN2A gene was analysed as outlined previously (Liu et al, 1995(Liu et al, , 1999. All of the patients analysed in this study lacked any functional mutations within 1 kilobase (kb) of the promoter and 5'UTR sequences directly upsteam of the ATG initiation codon and in exons 1 and 2 of the CDKN2A gene (data not shown).…”

Section: Abstract: Familial Melanoma; Cdk6mentioning

confidence: 93%

Lack of germline CDK6 mutations in familial melanoma

et al. 2000

Self Cite

View full text Add to dashboard Cite

Germline mutations in genes encoding several components of the retinoblastoma pathway have been linked with inherited predisposition to melanoma. Most commonly, such mutations involve CDKN2A, a cyclindependant kinase inhibitor of two kinases, CDK4 and CDK6, which phosphorylate the retinoblastoma protein (pRB) and thereby promote passage through the G 1 /S cell-cycle restriction point. Less frequently, germline mutations in the CDK4 gene have also been linked with an increased risk of melanoma. Despite the sequence and functional homology between CDK4 and CDK6, the role of germline mutations in CDK6 in melanoma predisposition is unknown. We detected no CDK6 mutations within the p16 (CDKN2A) binding domain in index cases from 60 melanoma-prone kindreds that lacked germline mutations in the coding regions of either CDKN2A or within the entire CDK4 coding region. We conclude that germline mutations in CDK6 do not make a signi®cant contribution to melanoma predisposition. Oncogene (2000) 19, 1849 ± 1852. Keywords: familial melanoma; CDK6Between 8 and 12% of melanoma cases arise in families with a genetic predisposition to the disease (Tucker and Goldstein, 1995). In a subset of these kindreds, germline coding mutations of the CDKN2A gene (on human chromosome 9p21) co-segregate with cases of melanoma (Hussussian et al., 1994;Walker et al., 1995;Dracopoli and Fountain, 1996;FitzGerald et al., 1996; NL and DH, unpublished). The CDKN2A gene product ± designated p16 ± is a cyclin-dependent kinase (CDK) inhibitor (CDKI). p16 plays a key regulatory role in the retinoblastoma (Rb) pathway at the G 1 /S cell-cycle restriction point by inhibiting the phosphorylation of Rb via CDK4/6 (Kato et al., 1993;Weinberg, 1995;Ruas and Peters, 1998). The genetic basis for melanoma in families and individuals that lack coding mutations of CDKN2A is not well understood at this time. Possible explanations include non-coding mutations of CDKN2A; alterations in other genes located at 9p21; and mutations of other major or minor melanoma predisposition genes located elsewhere in the human genome.Genetic alterations of two other members of the Rb pathway in addition to CDKN2A have been linked with an increased risk of melanoma. Individuals harbouring germline mutations in the Rb gene and who have retinoblastoma as children show an increased risk of melanoma as adults (Draper et al., 1986;Traboulsi et al., 1988;Eng et al., 1993;Bataille et al., 1995). In addition, three melanoma prone families have been reported to possess germline mutations in the CDK4 gene that cosegregate with the disease. Two of these families possess a cysteine rather than the wild-type arginine at amino acid 24 (R24C; Zuo et al., 1996). More recently, an additional mutation at position 24 (R24H) was identi®ed in a single French kindred (Sou®r et al., 1998). Moreover, the R24C (and presumably the R24H) mutant protein has a reduced a nity for p16, resulting in relaxation of control at the G1/S restriction point. CDK6 shows considerable amino acid homology with CDK4 ( Figure...

show abstract

“…Finally, a mutation detected in the 5¢UTR, -34G4T, has been previously reported in melanoma kindreds, 25 and creates a premature start site for translation, thereby decreasing translation of the native protein. 31 The patient carrying this mutation reported a family history of pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling

et al. 2010

View full text Add to dashboard Cite

Germline mutations in CDKN2A have been reported in pancreatic cancer families, but genetic counseling for pancreatic cancer risk has been limited by lack of information on CDKN2A mutation carriers outside of selected pancreatic or melanoma kindreds. Lymphocyte DNA from consecutive, unselected white non-Hispanic patients with pancreatic adenocarcinoma was used to sequence CDKN2A. Frequencies of mutations that alter the coding of p16INK4 or p14ARF were quantified overall and in subgroups. Penetrance and likelihood of carrying mutations by family history were estimated. Among 1537 cases, 9 (0.6%) carried germline mutations in CDKN2A, including three previously unreported mutations. CDKN2A mutation carriers were more likely to have a family history of pancreatic cancer (P¼0.003) or melanoma (P¼0.03), and a personal history of melanoma (P¼0.01). Among cases who reported having a first-degree relative with pancreatic cancer or melanoma, the carrier proportions were 3.3 and 5.3%, respectively. Penetrance for mutation carriers by age 80 was calculated to be 58% for pancreatic cancer (95% confidence interval (CI) 8-86%), and 39% for melanoma (95% CI 0-80). Among cases who ever smoked cigarettes, the risk for pancreatic cancer was higher for carriers compared with non-carriers (HR 25.8, P¼2.1Â10 À13 ), but among nonsmokers, this comparison did not reach statistical significance. Germline mutations in CDKN2A among unselected pancreatic cancer patients are uncommon, although notably penetrant, especially among smokers. Carriers of germline mutations of CDKN2A should be counseled to avoid tobacco use to decrease risk of pancreatic cancer in addition to taking measures to decrease melanoma risk. Keywords: cyclin-dependent kinase inhibitor p16; genes; p16; pancreatic neoplasms INTRODUCTION Pancreatic cancer is associated with very poor survival rates, with long-term survivors limited to those with resected early stage tumors. However, detection of pancreatic cancer at an early stage is challenging, and this mandates identification of high-risk groups to be targeted for prevention and screening intervention.Since first observed by Lynch and Krush in 1968, 1 the incidence of pancreatic cancer has been noted to be increased in many families affected by inherited melanoma syndromes. In genetic analyses of these families, 20-40% of inherited increased melanoma susceptibility can be linked to mutations of the CDKN2A gene (p16/Ink4) located on chromosome 9p21. [2][3][4][5] As a result of the increased incidence of pancreatic cancer in melanoma families with CDKN2A mutations, it was hypothesized that mutations likely also predispose to pancreatic cancer development. 2 Mutations in CDKN2A have subsequently been described in familial pancreatic cancer kindreds, some without melanoma. 3,4 Somatic mutations of CDKN2A are present in up to 95% of pancreatic tumors. 5 These findings provide further support for the premise that CDKN2A mutations have an important role in the development of pancreatic cancer. Clinical findings in mutation carri...

show abstract

Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma

Cited by 249 publications

References 20 publications

Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma

Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma

Lack of germline CDK6 mutations in familial melanoma

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling

Contact Info

Product

Resources

About